Back to results
US 11,439,646 B2Granted
Anti-proliferative agents for treating PAH
AssigneePfizer Inc.
InventorSteven Martin Evans
Life of this patent
Estimating the term…
Abstract
Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
Claims3
A method for treating pulmonary artery hypertension (PAH) in a human in need thereof, which method comprises administering to the human an effective amount of an inhibitor of CDK4 and CDK6 selected from the group consisting of:
- 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d[pyrimidin-7(8H)-one,
- 7-cyclopentyl-N, N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, or
- 2-pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl),
- or pharmaceutically acceptable salts thereof.
1 more element
Dependencies are inferred from the claim text.